Literature DB >> 18612295

How many patents does a biopharmaceutical company need?

Deepak Kumar Parida1, Ritu Mehdiratta, Gayatri Saberwal.   

Abstract

Young biotech companies may not need extensive patent portfolios to survive or grow.

Mesh：

Year:  2008        PMID： 18612295     DOI： 10.1038/nbt0708-763

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


  4 in total

1.  Maintaining patents protecting biologics or small-molecule drugs.

Authors:  Ganesan Marimuthu; Sangita Kumari; Muthukrishnakumar Kandasamy; Srivatsan Raghunathan; Gayatri Saberwal
Journal:  Nat Biotechnol       Date:  2012-01-09       Impact factor: 54.908

2.  Dynamics of global disclosure through patent and journal publications for biopharmaceutical products.

Authors:  Harry Thangaraj; Craig J van Dolleweerd; Edward G McGowan; Julian K-C Ma
Journal:  Nat Biotechnol       Date:  2009-07       Impact factor: 54.908

3.  Antibodies and other biopharmaceuticals.

Authors:  Alois Jungbauer
Journal:  Biotechnol J       Date:  2008-10       Impact factor: 4.677

4.  US FDA Drug Approvals are Persistent and Polycyclic: Insights into Economic Cycles, Innovation Dynamics, and National Policy.

Authors:  Iraj Daizadeh
Journal:  Ther Innov Regul Sci       Date:  2021-03-30       Impact factor: 1.778
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.